

# Clinical trials of quinidine

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
<b>quinidine vs no treatment</b>			
Hillestad , 1971 n=NA	-	-	Parallel groups
Sodermark , 1975 n=110/75 follow-up: 12 months	Quinidine 1.2 - 1.8 g/d versus no treatment	Persistent AF or AF1 lasting <3 year	Parallel groups open
<b>quinidine vs placebo</b>			
Byrne Quinn , 1979 n=32/42 follow-up: 12 months	Quinidine 1.2 g/d versus placebo	Persistent AF	Parallel groups double blind
Lloyd (quinidine vs placebo) , 1984 n=NA follow-up: 6 months	quinidine 1.4 g/d versus placebo	Persistent AF lasting 1 month to 3 years	Parallel groups double blind
PAFAC (quinidine vs placebo) , 2004 n=377/88 follow-up: 12 months	Quinidine 0,480 g/d (+ verapamil) versus placebo	Persistent AF lasting >7 daysil	Parallel groups double blind
SOPAT (quinidine vs placebo) , 2004 n=518/251 follow-up: 12 months	Quinidine 0,320 or 0,480 g/d (+ verapamil) versus placebo	Paroxysmal AF documented in the last 1 month@4	Parallel groups double blind
<b>quinidine vs digoxin</b>			
Steinbeck (quinidine vs digoxin) , 1988 n=15/15 follow-up: 12 months	Quinidine 1 g/d (+ digoxine) versus digoxine alone	Paroxysmal symptomatic AF of any duration	Parallel groups open
<b>quinidine vs disopyramide</b>			
Lloyd (quinidine vs disopyramide) , 1984 n=28/29 follow-up: 6 months	quinidine 1.4 g/d , quinidine 1.4 g/d versus	Persistent AF lasting 1 month to 3 years	Parallel groups double blind

continued...

Trial	Treatments	Patients	Trials design and methods
<b>quinidine vs flecainide</b>			
Steinbeck (quinidine vs flecainide) , 1988 n=15/15 follow-up: 12 months	Quinidine 1 g/d (+ digoxine) , Quinidine 1 g/d (+ digoxine) versus	Paroxysmal symptomatic AF of any duration	Parallel groups open
<b>quinidine vs sotalol</b>			
Hohnloser , 1995 n=25/25 follow-up: 6 months	Quinidine 1 g/d versus sotalol 240-320 mg/dt	Persistent AF between 2 days and 6 months	Parallel groups open
Juul-Moller , 1990 n=85/98 follow-up: 6 months	Quinidine 1,2 g/d versus Sotalol 160-320 mg/dt	Persistent AF between 2 months and 1 year	Parallel groups open
Kalusche , 1994 n=41/41 follow-up: 12 months	Quinidine 1 g/d versus Sotalol 240-400 mg/dt	AF lasting from 2 weeks to 2 years	Parallel groups open
PAFAC (quinidine vs sotalol) , 2004 n=377/383 follow-up: 12 months	Quinidine 0,480 g/d (+ verapamil) , Quinidine 0,480 g/d (+ verapamil) versus	Persistent AF lasting >7 daysil	Parallel groups double blind
SOCESP , 1999 n=63/58 follow-up: 6 months	Quinidine 700 mg/d versus sotalol 240 mg/d	AF lasting <6 months	Parallel groups open
SOPAT (quinidine vs sotalol) , 2004 n=518/264 follow-up: 12 months	Quinidine 0,320 or 0,480 g/d (+ verapamil) , Quinidine 0,320 or 0,480 g/d (+ verapamil) versus	Paroxysmal AF documented in the last 1 month@4	Parallel groups double blind

More details and results :

- antiarrhythmic drugs for atrial fibrillation in maintaining sinus rhythm after cardioversion at <http://www.trialresultscenter.org/go-Q113>

## References

### Hillestad, 1971:

Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study. Br Heart J 1971;33:518-21 [4934041]

### Sodermark, 1975:

Sdermark T, Jonsson B, Olsson A, Or L, Wallin H, Edhag O, Sjgren A, Danielsson M, Rosenhamer G Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. *Br Heart J* 1975;37:486-92 [[1093559](#)]

**Byrne Quinn, 1979:**

Byrne-Quinn E, Wing AJ Maintenance of sinus rhythm after DC reversion of atrial fibrillation. A double-blind controlled trial of long-acting quinidine bisulphate. *Br Heart J* 1970;32:370-6 [[4911757](#)]

**Lloyd (quinidine vs placebo), 1984:**

Lloyd EA, Gersh BJ, Forman R The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo. *S Afr Med J* 1984;65:367-9 [[6367096](#)]

**PAFAC (quinidine vs placebo), 2004:**

Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. *Eur Heart J* 2004;25:1385-94 [[15302102](#)]

Fetsch T, Burschel G, Breithardt G, Engberding R, Koch HP, Lukl J, Trappe HJ, Treese N [Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study] *Z Kardiol* 1999;88:195-207 [[10355070](#)]

**SOPAT (quinidine vs placebo), 2004:**

Patten M, Koch HP, Sonntag F, Lderitz B, Meinertz T [Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians] *Z Kardiol* 1999;88:185-94 [[10355069](#)]

Patten M, Maas R, Bauer P, Lderitz B, Sonntag F, Dluzniewski M, Hatala R, Opolski G, Mller HW, Meinertz T Suppression of paroxysmal atrial tachyarrhythmias—results of the SOPAT trial. *Eur Heart J* 2004;25:1395-404 [[15321697](#)]

**Steinbeck (quinidine vs digoxin), 1988:**

Steinbeck G, Doliwa R, Bach P [Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti-arrhythmia agents?] *Dtsch Med Wochenschr* 1988;113:1867-71 [[3143539](#)]

**Lloyd (quinidine vs disopyramide), 1984:**

**Steinbeck (quinidine vs flecainide), 1988:**

Steinbeck G, Doliwa R, Bach P *Dtsch Med Wochenschr* 1988;113:1867-71 [[3143539](#)]

**Hohnloser, 1995:**

Hohnloser SH, van de Loo A, Baedeker F Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. *J Am Coll Cardiol* 1995;26:852-8 [[7560608](#)]

**Juul-Moller, 1990:**

Juul-Mller S, Edvardsson N, Rehnqvist-Ahlberg N Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. *Circulation* 1990;82:1932-9 [[2242519](#)]

**Kalusche, 1994:**

Kalusche D, Stockinger J, Betz P, Roskamm H [Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation—conversion and 12-month follow-up—a randomized comparison] *Z Kardiol* 1994;83 Suppl 5:109-16 [[7846939](#)]

**PAFAC (quinidine vs sotalol), 2004:**

Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. *Eur Heart J* 2004;25:1385-94 [[15302102](#)]

**SOCESP, 1999:**

de Paola AA, Veloso HH Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of So Paulo. Am J Cardiol 1999;84:1033-7 [[10569659](#)]

Veloso HH, de Paola AA [Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP] Arq Bras Cardiol 1998;70:43-9 [[9629687](#)]

**SOPAT (quinidine vs sotalol), 2004:**